Clinical Trials
20 trialsNCT06503146 2026-05-19
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07089641 2026-04-07
ERAS801-SARG
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
NCT04459273 2026-02-05
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT02902757 2025-12-17
FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma
Jonsson Comprehensive Cancer Center
Phase NA Completed
NCT07118176 2025-08-12
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT06632860 2025-07-09
A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Recruiting
NCT06815029 2025-06-26
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
City of Hope Medical Center
Phase 1 Recruiting
NCT03732352 2024-11-12
18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT01246869 2024-10-01
Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water
University of Utah
Phase 1 Terminated
NCT05549024 2024-07-05
68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Recruiting
NCT04219969 2024-05-09
FDG PET-MRI for the Diagnosis of Spinal Cord Lesions
M.D. Anderson Cancer Center
Phase NA Completed
NCT05054998 2024-05-01
Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases
M.D. Anderson Cancer Center
Phase 4 Completed
NCT00662506 2023-06-06
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00813566 2022-04-27
Multi-Tracer PET Assessment of Primary Brain Tumors
University of Utah
Phase 1 Completed
NCT04315584 2020-03-24
FDG and FDOPA PET Demonstration of Functional Brain Abnormalities
University of Virginia
Phase EARLY_PHASE1 Unknown
NCT01806675 2019-10-03
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Stanford University
Phase 1/2 Completed
NCT00381797 2017-11-28
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00060008 2014-04-04
Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma
Children's Hospital of Philadelphia
Phase NA Terminated
NCT00253461 2012-03-20
11C Topotecan PET Imaging
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated